IBEX Technologies Inc., an innovator in the development of diagnostics and therapeutics for the management of cancer and arthritis, today announced findings from a recently published rheumatoid arthritis (RA) clinical study that confirms the utility of the Company’s serum biomarkers for measuring degradation and synthesis of cartilage.
